IMNM SEC Filings: 8-K, 10-Q, S-3 & 424B – Immunome

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWImmunome Reports Third Quarter 2026 Financial Results and Provides Business Update

Nov 9, 2026

8-K

Immunome Amends License Agreement with Bristol-Myers Squibb, Eliminating Future Milestones and Royalties

Oct 5, 2026

8-K

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 11, 2026

8-K

Immunome, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 12, 2026

8-K

Immunome Reports First Quarter 2026 Financial Results and Pipeline Progress

May 12, 2026

8-K

Immunome Reports Full Year 2025 Financial Results and Provides Business Update, Highlighting Varegacestat NDA Plan

Mar 3, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Dec 17, 2025

424B5

SHELF OFFERING | Offering amount: $400,000,000 | Bank: Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC, Guggenheim Securities, Wedbush, PacGrow, LifeSci Capital

Dec 15, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Jan 30, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Jan 29, 2025

424B5

Common Stock

May 14, 2024

424B5

Common Stock Preferred Stock Debt Securities Warrants

Feb 14, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-3ASR

NEWNovember 2026 SHELF + ATM

Nov 9, 2026

S-3ASR

NEWSHARE RESALE REGISTRATION

Nov 9, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 11, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 3, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 19, 2025

S-3ASR

SHARE RESALE REGISTRATION | Shares amount: 1,805,502 | Share price: $9.33

Nov 22, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

VANGUARD CAPITAL MANAGEMENT LLC (Filed by)

Oct 30, 2026

Higgins Jack (Reporting)

Sep 15, 2026

144

Form 144 - Report of proposed sale of securities

Sep 11, 2026

SCHEDULE 13G/A

T. Rowe Price Investment Management, Inc. (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

Sirenia Capital Management LP (Filed by)

Aug 14, 2026

Barchas Isaac (Reporting)

Aug 12, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 28, 2023

CORRESP

Form CORRESP - Correspondence

Nov 22, 2023

LETTER

Form UPLOAD - SEC-generated letter

Nov 20, 2023

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 29, 2023

CORRESP

Form CORRESP - Correspondence

Aug 25, 2023

LETTER

Form UPLOAD - SEC-generated letter

Aug 11, 2023

Immunome, Inc. IMNM · SEC Filings